By Date


  • 29-November-2018

    English, PDF, 757kb

    How resilient were OECD health care systems during the “refugee crisis”? - OECD Migration Policy Debates

    This edition of Migration Policy Debates reviews current challenges and good practices for making OECD health systems more resilient in the face of a refugee crisis, drawing from a debate at a joint OECD, the World Bank and the Center for Mediterranean Integration conference on “Human Resources for Health (HRH): Integration of Refugees into Host Community Health Systems”.

    Related Documents
  • 29-November-2018

    English

    Pharmaceuticals

    Pharmaceuticals have contributed to improvements in life expectancy and quality of life of many patients. Medicines can cure, relieve symptoms, delay the onset of disease and prevent complications. They often offer good value for money. However, recent trends raise a number of concerns.

    Related Documents
  • 29-November-2018

    English

    Patient Safety

    Patient harm is estimated to be the 14th leading cause of global disease burden and exerts considerable costs to patients, health systems and societies. Overall, available evidence suggest that at least 15% of hospital expenditure and activity in OECD countries can be attributed to treating safety failures.

    Related Documents
  • 29-November-2018

    English

    Health Working Papers

    The OECD Health Working Papers series is designed to make available to a wider readership health studies prepared for use within the OECD.

    Related Documents
  • 29-November-2018

    English

    Pharmaceutical Innovation and Access to Medicines

    This report reviews the important role of medicines in health systems, describes recent trends in pharmaceutical expenditure and financing, and summarises the approaches used by OECD countries to determine coverage and pricing. It then highlights current issues for policy makers, such as the increasing prices of new medicines; concerns about the value of spending in some therapeutic areas; challenges in anticipating the arrival of very effective medicines for highly prevalent diseases; sharp price increases in off-patent products; and the apparent misalignment of current incentives for the development of treatments for certain conditions. The report also describes the role of the biopharmaceutical industry in OECD economies, examines the process of pharmaceutical R&D and its financing, and looks at the risks, costs and return from R&D investment for the industry. Examining trends in the industry over time, it shows that productivity of R&D expenditure has declined; that the duration of market exclusivity has remained relatively stable; that new medicines are increasingly being developed for small patient populations; and that the industry as a whole has remained highly profitable for investors. Lastly, the report presents a range of policy options for consideration by policy makers, to support the development of effective and co-ordinated responses to the identified challenges.
  • 28-November-2018

    English

    Mental Health

    Mental disorders account for one of the largest and fastest growing categories of the burden of disease worldwide. Mental ill-health can have devastating effects on individuals, families and communities, with one in every two people experiencing a mental illness in their lifetime. As many as 80% of those with a common mental disorder, and up to 50% of those with a severe mental disorder, do not seek or receive treatment.

  • 26-November-2018

    English

    Health Workforce

    Health workers are crucial for ensuring access to high quality care for the whole population. The OECD advises countries on how to meet future demand for health professionals and how to manage the supply of health workers, by reviewing policies related to education and training, continuous professional development, geographic distribution and immigration.

    Related Documents
  • 26-November-2018

    English

    Waiting Times

    Over the past decade, many OECD countries have introduced new policies to tackle excessive waiting times for elective treatments with some success. However, in the wake of the recent economic downturn and severe pressures on public budgets, waiting times may rise again, and it is important to understand which policies work.

  • 22-November-2018

    English

    Health at a Glance: Europe 2018 - State of Health in the EU Cycle

    Health at a Glance: Europe 2018 presents comparative analyses of the health status of EU citizens and the performance of the health systems of the 28 EU Member States, 5 candidate countries and 3 EFTA countries. It is the first step in the State of Health in the EU cycle of knowledge brokering. This publication has two parts. Part I comprises two thematic chapters, the first focusing on the need for concerted efforts to promote better mental health, the second outlining possible strategies for reducing wasteful spending in health. In Part II, the most recent trends in key indicators of health status, risk factors and health spending are presented, together with a discussion of progress in improving the effectiveness, accessibility and resilience of European health systems.
  • 22-November-2018

    English, PDF, 2,328kb

    Health at a Glance: Europe 2018 - Chartset

    Access key results from "Health at a Glance: Europe 2018" in this chartset.

    Related Documents
  • << < 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 > >>